In lung cancer patients, NSD2 overexpression and uncontrolled H3K36me2 enrichment lead to rapid tumor progression and also to a poorer outcome, and NSD2 inhibition disrupts the activation of RAS-target genes, contributing to the inhibition of the RAS-mediated oncogenic transcriptional programs [45,52]. This evidence concerns the gene NSD2 and lung cancer.